ResMed (ASX:RMD) Total Debt per Share: A$0.83 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:RMD ResMed Inc ASX:RMD
97 GF Score
Price A$29.99
GF Value A$38.01
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is ResMed Total Debt per Share?

ResMed ASX:RMD +3.59% 97 Total Debt per Share is A$0.83 as of Mar. 2026. GuruFocus rates ASX:RMD with a GF Score™ of 97/100 and a GF Value™ of A$38.01 (Modestly Undervalued). The stock has 1 warning sign investors should review.

A$0.83 (As of Mar. 2026)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. ResMed's Total Debt Per Share for the quarter that ended in Mar. 2026 was A$0.83.

ResMed Total Debt per Share Historical Data

* Premium members only.

The historical data trend for ResMed's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ResMed Total Debt per Share Chart

ResMed Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Debt per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.71 0.89 1.60 0.90 0.89

ResMed Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Debt per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.91 0.89 0.88 0.88 0.83
ASX:RMD
97GF Score
ResMed Inc ASX:RMD
Total Debt per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ResMed Total Debt per Share Calculation

ResMed's Total Debt Per Share for the fiscal year that ended in Jun. 2025 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(1,246+62)/1,464
=0.89

ResMed's Total Debt Per Share for the quarter that ended in Mar. 2026 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(789+412)/1,450
=0.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Debt per Share →
What does a Total Debt per Share of A$0.83 mean?
ResMed (ASX:RMD) has a Total Debt per Share of A$0.83 as of Mar. 2026. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on ResMed and its competitors.
Is ResMed's Total Debt per Share too high?
ResMed's current Total Debt per Share is A$0.83. Overall, ResMed has a GF Score™ of 97/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ResMed's Total Debt per Share compare to MDLN and WST?
ResMed's Total Debt per Share of A$0.83 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Debt per Share for a Medical Devices & Instruments company?
A good Total Debt per Share depends on the Medical Devices & Instruments industry context. However, Total Debt per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Debt per Share mean?
A high Total Debt per Share can signal that a stock is expensive relative to its fundamentals. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on ResMed and its competitors. ResMed's current Total Debt per Share is A$0.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ResMed stock overvalued right now?
Based on GuruFocus' analysis, ResMed (ASX:RMD) is currently considered Modestly Undervalued. The stock's GF Value™ is A$38.01, compared to a current price of A$29.99 — trading 21.1% below its estimated fair value. The current Total Debt per Share is A$0.83. ResMed's overall GF Score™ is 97/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Debt per Share calculated?
Total Debt per Share is calculated from a company's financial statements. For ResMed (ASX:RMD), the current Total Debt per Share is A$0.83 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ResMed (ASX:RMD) Overvalued in 2026?

Based on GuruFocus' analysis, ResMed stock appears to be undervalued. The current stock price of A$29.99 is trading 21.1% below its estimated GF Value™ of A$38.01. GuruFocus considers ResMed to be Modestly Undervalued.

Key valuation signals for ASX:RMD:

  • Total Debt per Share: A$0.83
  • GF Value™: A$38.01 vs. price of A$29.99 (21.1% below fair value)
  • GF Score™: 97/100 with 1 warning sign

No single metric tells the full story. See the ASX:RMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ResMed Business Description

Address 9001 Spectrum Center Boulevard, San Diego, CA, USA, 92123
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
97GF Score

Get the complete analysis for ASX:RMD

Total Debt per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$29.99
Price
A$38.01
GF Value